Aprofol achieves milestone in patent applications
July 10, 2019
Since 2016, Generis is a shareholder of the life science start-up Aprofol and supports it in various business areas. With the patent application at the end of June, Aprofol took an important step.
Based on the principle “services for shares” Generis is engaged in the life-science start-up Aprofol AG. Aprofol focuses on the development of folat-based health care products.
Bio-active folates have great potential to prevent and treat a range of chronic diseases. With the current definitive patent application at the end of June, a milestone was reached and an attractive basis laid for cooperation partners from the pharmaceutical industry in topical applications.
Generis supports Aprofol in the management, investor relationship and backoffice functions. www.aprofol.com / www.ocufolin.shop
